Media

News

Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

November 06, 2019

Bayer responds to coverage recommendation by the Pan-Canadian Oncology Drug Review (pCODR) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients

Read more
October 29, 2019

Bayer Fund helps Canadian farmers strengthen rural communities through its Canada’s Farmers Grow Communities Program

Read more
October 22, 2019

4-H Canada and Bayer Renew Five-Year Commitment to Invest in Youth through STEM

Read more
October 16, 2019

Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer

79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications / Similar ORR of 75% in patients with brain metastases1, adding to the previously reported evidence for larotrectinib’s activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved; median duration of response (mDOR) of nearly three years1 / Largest dataset with longest follow-up of any TRK inhibitor illustrates favourable safety profile across ages and tumour types Read more
October 02, 2019

Bayer Fund shares over $100,000 in funding with students through its Opportunity Scholarship Program

67 Canadian students pursuing post-secondary education in agriculture and food-related disciplines Read more
September 03, 2019

Bayer completes sale of iconic Coppertone™ brand to Beiersdorf

Divestiture enables Bayer to focus on core OTC business Read more
July 30, 2019

Health Canada approves VITRAKVI® (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion

Read more
July 22, 2019

Yellow Wood Partners to acquire iconic Dr. Scholl’s™ brand from Bayer

Yellow Wood Partners and Bayer announced today that Yellow Wood Partners has entered into a definitive agreement to buy the Dr. Scholl’s™ business from Bayer for a purchase price of 585 million U.S. dollars. Read more
May 14, 2019

Beiersdorf to acquire iconic Coppertone™ brand from Bayer

Divestiture enables Bayer to focus on core OTC business Read more
April 04, 2019

Delaro fungicide now registered for cereals

The new registration delivers exceptional and long-lasting control of leaf diseases in cereals Read more